Australian Group on Antimicrobial Resistance (AGAR) Australian Gram-negative Surveillance Outcome Program (GnSOP) Bloodstream Infection Annual Report 2021

Authors

  • Jan M Bell Australian Group on Antimicrobial Resistance, Adelaide, South Australia, Australia
  • Alicia Fajardo Lubian Westmead Institute for Medical Research, Westmead, New South Wales, Australia; University of Sydney, New South Wales, Australia
  • Sally R Partridge Westmead Institute for Medical Research, Westmead, New South Wales, Australia; University of Sydney, New South Wales, Australia; Westmead Hospital, Westmead, New South Wales, Australia
  • Thomas Gottlieb University of Sydney, New South Wales, Australia; Department of Microbiology and Infectious Diseases, Concord Hospital, Concord, New South Wales, Australia
  • Jenny Robson Microbiology and Infectious Diseases, Sullivan Nicolaides Pathology, Bowen Hills, Queensland
  • Jonathan R Iredell Westmead Institute for Medical Research, Westmead, New South Wales, Australia; University of Sydney, New South Wales, Australia; Westmead Hospital, Westmead, New South Wales, Australia
  • Denise A Daley Australian Group on Antimicrobial Resistance, Fiona Stanley Hospital, Murdoch, Western Australia, Australia
  • Geoffrey W Coombs Antimicrobial Resistance and Infectious Diseases (AMRID) Research Laboratory, Murdoch University, Murdoch, Western Australia, Australia; Department of Microbiology, PathWest Laboratory Medicine-WA, Fiona Stanley Hospital, Murdoch, Western Australia, Australia

DOI:

https://doi.org/10.33321/cdi.2022.46.78

Keywords:

Australian Group on Antimicrobial Resistance (AGAR), antimicrobial resistance, bacteraemia, gram-negative, Escherichia coli, Enterobacter, Klebsiella

Abstract

The Australian Group on Antimicrobial Resistance (AGAR) performs regular period-prevalence studies to monitor changes in antimicrobial resistance in selected enteric gram-negative pathogens. The 2021 survey was the ninth year to focus on bloodstream infections caused by Enterobacterales, and the seventh year where Pseudomonas aeruginosa and Acinetobacter species were included.
The 2021 survey tested 8,947 isolates, comprising Enterobacterales (8,104; 90.6%), P. aeruginosa (745; 8.3%) and Acinetobacter species (98; 1.1%), using commercial automated methods. The results were analysed using Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints (January 2022). Of the key resistances, resistance to the third-generation cephalosporin ceftriaxone was found in 12.5%/12.5% (CLSI/EUCAST criteria) of Escherichia coli and in 6.1%/6.1% of Klebsiella pneumoniae. Resistance rates to ciprofloxacin were 12.3%/12.3% for E. coli; 7.2%/7.2% for K. pneumoniae; 5.4%/5.4% for Enterobacter cloacae complex; and 3.7%/8.0% for P. aeruginosa. Resistance rates to piperacillin-tazobactam were 2.8%/6.5%; 2.9%/9.9%; 18.4%/28.1%; and 6.9%/12.8% for the same four species, respectively. Seventeen Enterobacterales isolates from 17 patients were shown to harbour a carbapenemase gene: 12 blaIMP-4; two blaNDM-7; one blaNDM-1; one blaOXA-181; and one blaKPC-2. No transmissible carbapenemase genes were detected among P. aeruginosa or Acinetobacter isolates in the 2021 survey.

Downloads

Download data is not yet available.

References

Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. 32nd ed. CLSI supplement M100. Wayne, PA: CLSI; 16 February 2022.

The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 12.0. Basel: EUCAST; 1 January 2022. Available from: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_12.0_Breakpoint_Tables.pdf.

Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–81. doi: https://doi.org/10.1111/j.1469-0691.2011.03570.x.

Seemann T, Goncalves da Silva A, Bulach DM, Schultz MB, Kwong JC, Howden BP. Nullarbor. San Francisco: Github; 2020. Available from: https://github.com/tseemann/nullarbor.

Seemann T. Abricate. San Francisco: Github; 2020. Available from: https://github.com/tseemann/abricate.

National Center for Biotechnology Information (NCBI). AMRFinderPlus. [Website.] Bethesda; United States National Library of Medicine, NCBI: 2020. Available from: https://ncbi.nlm.nih.gov/pathogens/antimicrobial-resistance/AMRFinder/.

Hunt M, Mather AE, Sánchez-Busó L, Page AJ, Parkhill J, Keane JA et al. ARIBA: rapid antimicrobial resistance genotyping directly from sequencing reads. Microb Genom. 2017;3(10):e000131. doi: https://doi.org/10.1099/mgen.0.000131.

Alcock BP, Raphenya AR, Lau TTY, Tsang KK, Bouchard M, Edalatmand A et al. CARD 2020: antibiotic resistome surveillance with the comprehensive antibiotic resistance database. Nucleic Acids Res. 2020;48(D1):D517–25. doi: https://doi.org/10.1093/nar/gkz935.

Turnidge JD, Gottlieb T, Mitchell D, Pearson J, Bell JM, on behalf of the Australian Group for Antimicrobial Resistance (AGAR). Gram-negative Survey: 2011 Antimicrobial Susceptibility Report. AGAR; 2012. Available from: http://agargroup.org.au/wp-content/uploads/2017/08/AGAR-GNB11-Report-FINAL.pdf.

Sheng WH, Badal RE, Hsueh PR, on behalf of the SMART Program. Distribution of extended-spectrum ß-lactamases, AmpC ß-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: results of the study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother. 2013;57(7):2981–8. doi: https://doi.org/10.1128/AAC.00971-12.

World Health Organization (WHO) Regional Office for Europe/European Centre for Disease Prevention and Control (ECDC). Antimicrobial resistance surveillance in Europe 2022 – 2020 data. Copenhagen: WHO Regional Office for Europe; 26 January 2022. Available from: https://apps.who.int/iris/handle/10665/351141.

ECDC. Data from the ECDC Surveillance Atlas – Antimicrobial resistance. [Webpage.] Solna: ECDC; 2022. Available from: https://www.ecdc.europa.eu/en/antimicrobial-resistance/surveillance-and-disease-data/data-ecdc.

Australian Commission on Safety and Quality in Health Care (ASCQHC). National Safety and Quality Health Service Standards. 2nd ed; updated May 2021. Sydney: ACSQHC; May 2021. Available from: https://www.safetyandquality.gov.au/publications-and-resources/resource-library/national-safety-and-quality-health-service-standards-second-edition.

ACSQHC. AURA 2021: fourth Australian report on antimicrobial use and resistance in human health. Sydney: ACSQHC; 27 August 2021. Available from: https://www.safetyandquality.gov.au/our-work/antimicrobial-resistance/antimicrobial-use-and-resistance-australia-surveillance-system/aura-2021.

Australian Government Department of Health and Aged Care. PBS News. Revised PBS listings for antibiotic use from 1 April 2020. [Internet.] Canberra: Australian Government Department of Health and Aged Care; 20 March 2020. Available from: https://www.pbs.gov.au/info/news/2020/03/revised_pbs_listings_for_antibiotic_use_from_1_april_2020.

Downloads

Published

17/11/22

How to Cite

Bell, Jan M, Alicia Fajardo Lubian, Sally R Partridge, Thomas Gottlieb, Jenny Robson, Jonathan R Iredell, Denise A Daley, and Geoffrey W Coombs. 2022. “Australian Group on Antimicrobial Resistance (AGAR) Australian Gram-Negative Surveillance Outcome Program (GnSOP) Bloodstream Infection Annual Report 2021 ”. Communicable Diseases Intelligence 46 (November). https://doi.org/10.33321/cdi.2022.46.78.

Issue

Vol. 46 (2022)

Section

Annual report

Categories

License

Copyright (c) 2022 Communicable Diseases Intelligence

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Most read articles by the same author(s)

1 2 3 4 5 6 > >>